Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement

Area of Science:

• Nutritional Biochemistry
• Cardiovascular Physiology
• Pharmacology

Background:

• The Energy Formula (EF) combines niacin-bound chromium (III), Withania somnifera, caffeine, D-ribose, and amino acids.
• These components were selected for their known cardioprotective and energy-boosting properties.
• The study aimed to evaluate the safety and efficacy of EF in a rat model.

Purpose of the Study:

• To investigate the effects of oral EF supplementation on myocardial energy levels and cardioprotective ability.
• To assess the safety profile of EF in male and female Sprague-Dawley rats over a 90-day period.
• To evaluate EF's impact on cardiovascular function following ischemia-reperfusion injury.

Main Methods:

• Rats were orally supplemented with EF for 90 days.
• Myocardial ischemia-reperfusion injury was induced at 30 and 90 days.
• Cardiovascular functions, myocardial energy markers (ATP, CP), and safety indicators were monitored.

Main Results:

• EF supplementation resulted in significant improvements in cardiovascular functions and myocardial energy levels.
• No adverse effects were observed on lipid peroxidation or hepatic enzyme activities.
• EF treatment led to reduced infarct size in the ischemic-reperfused myocardium.
• Rats treated with EF showed reduced body weight gain compared to controls.

Conclusions:

• The novel Energy Formula (EF) is a safe and effective supplement.
• EF demonstrates significant cardioprotective effects and enhances myocardial energy levels.
• EF holds potential for boosting energy and protecting the heart.